Clinical Commander

Back to dossier
cardio.atrial_flutter.cardioversion-failed.v1PRODUCTION
cardio.atrial_flutter.cardioversion-failed.v1

Refractory atrial flutter — cardioversion-failed

cardiologyacutechronicadult
Hard-required inputs
0 / 12
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Persistent flutter despite ≥2 DCCV attempts at 200 J biphasic AND/OR ibutilide + amiodarone failure → refractory phenotype with fixed substrate. Three management arms: (1) catheter ablation Class I (CTI if typical, 3D mapping if atypical); (2) AVN ablation + pacemaker for symptomatic rate-control failure; (3) rate-control acceptance with indefinite AC — ACC/AHA 2024 (PMID 38753446)

Inputs
2
Actions
0
Advance rule
Set
Advance when

Refractory phenotype confirmed

Patient inputs (12)

Frailty + ablation candidacy + life expectancy for AVN ablation + pacemaker decision

HR target 80–110 in chronic flutter (rate-control acceptance); breakthrough RVR drives ablation expedition

Defines refractoriness severity; ≥2 failed CV → ablation; ≥2 failed ablations → AVN ablation pathway consideration

Confirms flutter morphology (typical vs atypical) — drives CTI ablation vs 3D mapping decision; rules out 1:1 conducted (rare with AAD); QTc baseline pre-AAD

LA enlargement >50 mm drives lower ablation success; EF reduced → cautious about non-DHP CCB; valvular HD often coexists

DOAC + AAD dose adjustment; contrast for 3D mapping; pre-ablation safety

Amiodarone toxicity baseline (TFTs / LFTs / PFTs) — required pre-amiodarone load given likely chronic exposure

Hemodynamic stability for ablation pre-op + intraprocedural; SBP <90 with RVR → AVN escalation

AC indication + lifelong duration given chronic substrate

HAS-BLED + peri-ablation bleed risk; LAA occlusion candidacy if AC contraindicated

Drives ablation aggressiveness — symptomatic refractory → expedited ablation; minimally symptomatic → rate-control acceptance acceptable

EXCLUDE LAA thrombus pre-ablation when not on therapeutic AC ≥3 wk — ACC/AHA 2024 (PMID 38753446); deferred ablation if thrombus present

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningpost_ablation_cardiac_tamponade
    Hypotension + new pericardial effusion within hours of ablation → emergent pericardiocentesis
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpost_ablation_atrioesophageal_fistula
    Fever + chest pain + new neurologic deficit 2–6 weeks post-LA ablation → emergency surgical evaluation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningavn_ablation_pacer_failure
    Pacer malfunction (loss of capture, sensing failure, lead displacement) in AVN-ablated patient — pacer-dependent → asystole risk
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepulmonary_vein_stenosis_post_pvi
    Cough + hemoptysis + dyspnea + chest pain 4–12 weeks post-PVI ablation (especially in atypical-LA flutter ablation candidates with prior PVI) → PV stenosis
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereac_bridging_error_pre_or_post_ablation
    Missed AC doses or incorrect bridging strategy pre-/post-ablation → thromboembolic event risk OR bleed risk
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereamiodarone_pulmonary_or_thyroid_toxicity
    New cough/dyspnea + interstitial pattern on CT (amio pulm toxicity) OR new thyroid dysfunction on q6m TFT screen — amiodarone toxicity in this often chronically-exposed population
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

Refractory atrial flutter — ablation-first pathway (CTI for typical, 3D mapping for atypical, AVN ablation + pacemaker for ablation-contraindicated symptomatic) + lifelong AC + lifestyle modification — ACC/AHA 2024 (Joglar PMID 38753446); LEGACY (Pathak PMID 25770315)
axis: refractory_aflutter_ablation_first_pathway
Selected axis "Refractory atrial flutter — ablation-first pathway (CTI for typical, 3D mapping for atypical, AVN ablation + pacemaker for ablation-contraindicated symptomatic) + lifelong AC + lifestyle modification — ACC/AHA 2024 (Joglar PMID 38753446); LEGACY (Pathak PMID 25770315)" by default fallback (first axis)
  • metoprolol_succinate
    first line
    beta_blocker
    50–100 mg PO daily titrate to HR 80–110 • PO • once daily
    triggers: chronic_rate_control_pre_ablation, no_HFrEF_decompensation
    Long-acting BB for refractory rate control bridge to ablation — ACC/AHA 2024 (PMID 38753446)
    rxcui 866427
  • diltiazem
    first line
    non_DHP_CCB
    120–360 mg PO daily; IV 0.25 mg/kg bolus → 5–15 mg/h infusion if breakthrough RVR • IV/PO • daily PO; bolus + infusion if breakthrough
    triggers: BB_intolerant, EF_preserved, COPD_with_bronchospasm
    AVN slowing alternative; AVOID in HFrEF EF<40 — ACC/AHA 2024 (PMID 38753446)
    rxcui 3443
  • amiodarone
    second line
    class_III_AAD
    150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance • IV/PO • load + daily
    triggers: rhythm_maintenance_pre_ablation, structural_HD, recurrent_flutter_post_ablation
    Bridge AAD to ablation in refractory cases; pulm/thyroid/LFT monitoring — ACC/AHA 2024 (PMID 38753446)
    rxcui 703
  • dofetilide
    second line
    class_III_AAD
    125–500 mcg PO BID per CrCl (REMS — inpatient initiation × 3 d) • PO • BID
    triggers: amiodarone_intolerance, baseline_QTc_<440, inpatient_REMS_initiation_available
    Alternative class III; dofetilide REMS — inpatient initiation with QTc + CrCl monitoring — ACC/AHA 2024 (PMID 38753446)
    rxcui 49247
  • sotalol
    second line
    class_III_AAD_BB
    80–160 mg PO BID inpatient initiation per CrCl + QTc • PO • BID
    triggers: amio_intolerance, sinus_HR_>=60_post_AVN_block, inpatient_initiation_available
    Class III with BB activity; QT prolongation risk — ACC/AHA 2024
    rxcui 7008
  • apixaban
    first line
    DOAC_factor_Xa
    5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) • PO • BID
    triggers: CHA2DS2VASc_>=2, pre_post_ablation, lifelong_AC_for_refractory_substrate
    Lifelong AC; therapeutic ≥3 wk pre-ablation OR TEE-guided strategy — ACC/AHA 2024 Class I (PMID 38753446); ARISTOTLE (PMID 21870978)
    rxcui 1364430
  • rivaroxaban
    first line
    DOAC_factor_Xa
    20 mg with food (15 mg if CrCl 15–50) • PO • once daily
    triggers: CHA2DS2VASc_>=2, apixaban_unavailable
    X-VeRT (PMID 24837375) — peri-CV efficacy = warfarin
    rxcui 1114195
  • warfarin
    comorbidity specific
    vitamin_K_antagonist
    5 mg daily; INR target 2–3 • PO • daily
    triggers: mechanical_valve, severe_mitral_stenosis, DOAC_contraindicated, severe_renal_failure_CrCl_<15
    Mechanical valve / severe MS / DOAC-ineligible — ACC/AHA 2024 (PMID 38753446)
    rxcui 11289
  • cti_catheter_ablation
    first line
    procedural_intervention
    Single linear ablation lesion at cavotricuspid isthmus • procedural • one-time
    triggers: typical_CTI_dependent_flutter, refractory_to_CV_AAD
    >95% acute success for typical flutter — Calkins 2007 (PMID 17572388); ACC/AHA 2024 Class I
  • avn_ablation_with_permanent_pacemaker
    rescue
    procedural_intervention
    Junctional ablation + pre-implanted permanent pacemaker (typically biventricular if EF reduced) • procedural • one-time
    triggers: symptomatic_rate_control_failure, standard_ablation_contraindicated_or_failed
    Last-line for refractory RVR — creates pacer-dependence; ACC/AHA 2024 IIa (PMID 38753446)

outpatient playbook — drug actions (3)

  1. 1. continue apixaban lifelong
    rxcui 1364430
    5 mg BID renal-adjusted • PO • BID
    trigger: Refractory substrate (lifelong AC even if ablation succeeds — high recurrence risk)
    ACC/AHA 2024 Class I (PMID 38753446)
  2. 2. discontinue amiodarone if SR maintained
    rxcui 703
    wean to off over 4–8 weeks if no recurrence at 3–6 mo • PO • taper
    trigger: SR confirmed post-ablation × 3 mo
    Minimize amiodarone toxicity — ACC/AHA 2024
  3. 3. minimize rate-control if successful CTI ablation
    rxcui 866427
    wean metoprolol over 4–8 weeks if no recurrence at 3 mo • PO • taper
    trigger: Successful ablation + no recurrence + no other indication for BB
    ACC/AHA 2024

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Persistent atrial flutter despite ≥2 DCCV attempts at max 200 J biphasic energy — refractory phenotype; Failed chemical CV with ibutilide AND amiodarone load — definitive AAD failure; Long-standing persistent flutter >1 year + structural LA remodeling — fixed substrate, low CV success expected.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Refractory atrial flutter — cardioversion-failed** (cardio.atrial_flutter.cardioversion-failed.v1).
Scope: Persistent flutter despite ≥2 DCCV attempts at 200 J biphasic AND/OR ibutilide + amiodarone failure → refractory phenotype with fixed substrate. Three management arms: (1) catheter ablation Class I (CTI if typical, 3D mapping if atypical); (2) AVN ablation + pacemaker for symptomatic rate-control failure; (3) rate-control acceptance with indefinite AC — ACC/AHA 2024 (PMID 38753446)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Refractory atrial flutter — ablation-first pathway (CTI for typical, 3D mapping for atypical, AVN ablation + pacemaker for ablation-contraindicated symptomatic) + lifelong AC + lifestyle modification — ACC/AHA 2024 (Joglar PMID 38753446); LEGACY (Pathak PMID 25770315)**.
1. metoprolol_succinate 50–100 mg PO daily titrate to HR 80–110 PO once daily (beta_blocker, first line) — Long-acting BB for refractory rate control bridge to ablation — ACC/AHA 2024 (PMID 38753446)
2. diltiazem 120–360 mg PO daily; IV 0.25 mg/kg bolus → 5–15 mg/h infusion if breakthrough RVR IV/PO daily PO; bolus + infusion if breakthrough (non_DHP_CCB, first line) — AVN slowing alternative; AVOID in HFrEF EF<40 — ACC/AHA 2024 (PMID 38753446)
3. amiodarone 150 mg IV bolus then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance IV/PO load + daily (class_III_AAD, second line) — Bridge AAD to ablation in refractory cases; pulm/thyroid/LFT monitoring — ACC/AHA 2024 (PMID 38753446)
4. dofetilide 125–500 mcg PO BID per CrCl (REMS — inpatient initiation × 3 d) PO BID (class_III_AAD, second line) — Alternative class III; dofetilide REMS — inpatient initiation with QTc + CrCl monitoring — ACC/AHA 2024 (PMID 38753446)
5. sotalol 80–160 mg PO BID inpatient initiation per CrCl + QTc PO BID (class_III_AAD_BB, second line) — Class III with BB activity; QT prolongation risk — ACC/AHA 2024
6. apixaban 5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) PO BID (DOAC_factor_Xa, first line) — Lifelong AC; therapeutic ≥3 wk pre-ablation OR TEE-guided strategy — ACC/AHA 2024 Class I (PMID 38753446); ARISTOTLE (PMID 21870978)
7. rivaroxaban 20 mg with food (15 mg if CrCl 15–50) PO once daily (DOAC_factor_Xa, first line) — X-VeRT (PMID 24837375) — peri-CV efficacy = warfarin
8. warfarin 5 mg daily; INR target 2–3 PO daily (vitamin_K_antagonist, comorbidity specific) — Mechanical valve / severe MS / DOAC-ineligible — ACC/AHA 2024 (PMID 38753446)
9. cti_catheter_ablation Single linear ablation lesion at cavotricuspid isthmus procedural one-time (procedural_intervention, first line) — >95% acute success for typical flutter — Calkins 2007 (PMID 17572388); ACC/AHA 2024 Class I
10. avn_ablation_with_permanent_pacemaker Junctional ablation + pre-implanted permanent pacemaker (typically biventricular if EF reduced) procedural one-time (procedural_intervention, rescue) — Last-line for refractory RVR — creates pacer-dependence; ACC/AHA 2024 IIa (PMID 38753446)

Setting playbook (outpatient) — Long-term post-ablation surveillance, AC management lifelong, lifestyle modification (LEGACY), screening for incident AF or recurrent AFL — ACC/AHA 2024 (PMID 38753446)
11. continue apixaban lifelong 5 mg BID renal-adjusted PO BID — Refractory substrate (lifelong AC even if ablation succeeds — high recurrence risk) (ACC/AHA 2024 Class I (PMID 38753446))
12. discontinue amiodarone if SR maintained wean to off over 4–8 weeks if no recurrence at 3–6 mo PO taper — SR confirmed post-ablation × 3 mo (Minimize amiodarone toxicity — ACC/AHA 2024)
13. minimize rate-control if successful CTI ablation wean metoprolol over 4–8 weeks if no recurrence at 3 mo PO taper — Successful ablation + no recurrence + no other indication for BB (ACC/AHA 2024)

Non-pharmacologic actions:
- Lifestyle: weight, alcohol limit, OSA treatment, exercise (LEGACY PMID 25770315)
- Vaccinations + secondary prevention bundle (ACC/AHA 2024)
- Pacer clinic q6m if AVN ablation (device standard)

AVOID / contraindication checks:
- Flecainide propafenone block if structural heart disease — CAST; ACC/AHA 2024
- Dofetilide REMS inpatient initiation_x_3d — ACC/AHA 2024 (PMID 38753446)
- Amiodarone monitor pulm thyroid LFT_q6m — ACC/AHA 2024
- Sotalol inpatient initiation CrCl adjusted — ACC/AHA 2024
- Non DHP CCB block if EF lt 40 — ACC/AHA 2024
- Ablation requires AC 3wk or TEE within 48h — ACC/AHA 2024 (PMID 38753446)
- DOAC renal dose adjustment — ESC 2024 (PMID 39050851)
- AVN ablation pacer dependence irreversible — ACC/AHA 2024

Monitoring

Regimen monitoring:
- telemetry continuous post ablation x 24h — Calkins 2007 (PMID 17572388)
- groin check first 4h then q4h x 24h post ablation — HRS 2007
- QTc serial dofetilide sotalol amiodarone — ACC/AHA 2024
- PFTs TFTs LFTs baseline then q6m on amiodarone — ACC/AHA 2024
- lifelong AC for refractory substrate — ACC/AHA 2024 Class I
- post LA ablation atrioesophageal fistula warning x 6 weeks — HRS 2007 (PMID 17572388)
- Holter at 3 6 12 mo post ablation for recurrence — Calkins 2007
- pacer clinic q6m if AVN ablation — device standard
- lifestyle modification alcohol weight OSA — LEGACY (PMID 25770315)

Setting (outpatient) monitoring:
- Cardiology + EP q3–6 mo first year, then annually (ACC/AHA 2024)
- Holter at 3, 6, 12 mo post-ablation (Calkins 2007)
- CBC + eGFR q6m on DOAC (ESC 2024)
- TFT/LFT/PFT q6m on amiodarone (ACC/AHA 2024)

Follow-up plan: EP at 4 weeks post-ablation; cardiology q3–6 mo; AC continuation lifelong; Holter at 3, 6, 12 mo for recurrence; lifestyle (alcohol, weight, OSA); pacer clinic q6m if AVN ablation; surveillance for atrioesophageal fistula warning weeks 2–6 post-LA ablation
- Close-out criterion: Follow-up booked

Monitoring phase: Telemetry × 24 h post-ablation; groin check first 4 h then q4h × 24 h; QTc on AAD; AC adherence; for AVN ablation patients — pacer interrogation + sensing/threshold checks

Disposition

Current setting: outpatient — Long-term post-ablation surveillance, AC management lifelong, lifestyle modification (LEGACY), screening for incident AF or recurrent AFL — ACC/AHA 2024 (PMID 38753446)

Disposition criteria:
- Continue chronic surveillance; cross-link to cardio.atrial_flutter.typical-cavotricuspid.v1 or atypical variant per dominant ECG morphology

Escalation triggers (move to higher acuity):
- Recurrent flutter despite ablation → EP for repeat ablation OR AVN ablation pathway — HRS 2007
- New AF after successful flutter ablation → AF management via cardio.afib.core.v1; same AC strategy
- Stroke / TIA on AC → workup + consider switch — ACC/AHA 2024
- AC bleed → hold + reverse + reassess long-term strategy (LAA occlusion if HAS-BLED ≥3) — ANNEXA-4

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Hypotension + new pericardial effusion within hours of ablation → emergent pericardiocentesis
- [LIFE_THREATENING] Fever + chest pain + new neurologic deficit 2–6 weeks post-LA ablation → emergency surgical evaluation
- [LIFE_THREATENING] Pacer malfunction (loss of capture, sensing failure, lead displacement) in AVN-ablated patient — pacer-dependent → asystole risk

Citations

- 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar Circulation 2024 PMID 38753446); ESC 2024 AF (Van Gelder PMID 39050851); HRS/EHRA/ECAS 2007 catheter ablation expert consensus (Calkins PMID 17572388) [PMID:38753446](https://pubmed.ncbi.nlm.nih.gov/38753446/)
- Cited evidence (PMID 39050851) [PMID:39050851](https://pubmed.ncbi.nlm.nih.gov/39050851/)
- Cited evidence (PMID 17572388) [PMID:17572388](https://pubmed.ncbi.nlm.nih.gov/17572388/)
- Cited evidence (PMID 19324313) [PMID:19324313](https://pubmed.ncbi.nlm.nih.gov/19324313/)
- Cited evidence (PMID 30874727) [PMID:30874727](https://pubmed.ncbi.nlm.nih.gov/30874727/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar Circulation 2024 PMID 38753446); ESC 2024 AF (Van Gelder PMID 39050851); HRS/EHRA/ECAS 2007 catheter ablation expert consensus (Calkins PMID 17572388) — PMID:38753446
  • Cited evidence (PMID 39050851) — PMID:39050851
  • Cited evidence (PMID 17572388) — PMID:17572388
  • Cited evidence (PMID 19324313) — PMID:19324313
  • Cited evidence (PMID 30874727) — PMID:30874727